The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. has announced a change in its voting rights structure following an acquisition by BlackRock, Inc., which now holds 7.81% of the voting rights in the company. This adjustment in holdings reflects a slight increase from previous figures and may impact the company’s governance and strategic decisions, potentially influencing its market positioning and stakeholder interests.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell engineering technology. The company provides cell-engineering platforms that enable the development of cell-based therapies and other advanced medicines.
YTD Price Performance: -41.36%
Average Trading Volume: 31,102
Technical Sentiment Signal: Strong Buy
Current Market Cap: £208.7M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.